About Robert Heft, Ph.D. :
Dr. Robert Heft served as President, Chief Executive Officer, and member of the Board of Directors of Enobia Pharma Inc. (Montreal, Quebec) from 2005-2012. In February 2012, Dr. Heft sold Enobia to Alexion Pharmaceuticals Inc. for USD 1.1 Billion, the largest-ever sale of a private, pre-commercial biopharmaceutical company. He has also held several senior positions with BioMarin Pharmaceutical Inc. (Novato, California) after selling the pharmaceutical assets of IBEX Pharmaceuticals Inc. (IBT: TSX, Montreal, Quebec) to BioMarin in 2001. Dr. Heft founded IBEX in 1986 and served as its President, Chief Scientist and member of its Board of Directors until 2001. He also served as Executive in Residence at Sectoral Asset Management as well as on the Board of Directors of BioCapital (Private Equity/Venture Capital), the Canadian Genetic Diseases Network and the Industrial Biotechnology Association of Canada.
Dr. Heft obtained his Ph.D. from the Massachusetts Institute of Technology in Genetic Engineering/Radiological Sciences in 1986 and was a Neurology Fellow at the Massachusetts General Hospital. Prior to that, he received a Masters degree in Nuclear Engineering from Cornell University and a Bachelor of Mechanical Engineering from McGill University.
Dr. Heft has published and been awarded several patents in the fields of coagulation, phenylketonuria, and hypophosphatasia. He has also received several awards for his work including Company of the Year (2012 Gold Leaf Award for Enobia Pharma) from BIOTECanada, Entrepreneur of the Year (Canada 2012) from the Canadian Venture Capital Association, and the Genesis Award (2012) from BioQuebec. Dr. Heft currently serves as Advisor to Sectoral Asset Management and is a member of the Board of Directors for Ra Pharmaceuticals (RARX), Parvus Therapeutics, and Clementia Pharmaceuticals (CMTA).
Mr. Heft joined the Lumos Board in 2014.